Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyAvalon Colorectal Screening Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedAvalon Healthcare SolutionsPolicy AHS - G2181 - Colorectal Cancer Screening

    Colorectal Cancer Screening

    Customize your policy alerts

    Sign up for avalon_healthcare_solutions Policy AHS - G2181 - Colorectal Cancer Screening alerts

    Get alerted when Policy AHS - G2181 - Colorectal Cancer Screening changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of colorectal cancer screening services, including stool-based tests, colonoscopy, CT colonography, flexible sigmoidoscopy, and follow-up colonoscopy after a positive non-colonoscopy test. Coverage applies based on member benefit eligibility, applicable government policies, age, and colorectal cancer risk.

    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyColorectal Cancer Screening
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionRefer a positive stool-based screening result for diagnostic colonoscopy.
    SourceLink
    POLICY UPDATE CHANGES

    Methylated Septin 9 testing using ColoVantage was changed to not meet coverage criteria.

    FIT-DNA testing using Cologuard is covered when limited to once every one to three years according to USPSTF guidelines.

    Cologuard Plus was added to the covered FIT-DNA screening options.

    Coverage was expanded to address members at least 45 years of age and members younger than 45 who are at risk for colorectal cancer.

    Follow-up colonoscopy after a positive non-colonoscopy screening test was added as a covered part of the screening process.

    Screening using cell-free DNA techniques, such as Guardant Shield, was added to the criteria.

    CPT/HCPCS codes 0537U and 0464U were added.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    45+Age at which benefit coverage applies
    45-75Annual FIT or gFOBT screening age range
    1-3 yearsCovered FIT-DNA screening interval
    10 yearsScreening colonoscopy interval
    75Average-risk screening not covered above age
    2Procedure codes added

    Colorectal Cancer Screening Coverage Criteria

    Annual FIT or gFOBT screening

    Covered when the individual is asymptomatic and meets the stated age range.

    Annual FIT or gFOBT screening: The individual is asymptomatic and 45 to 75 years of age.Age 45-75 years

    Annual screening with FIT is preferred; annual gFOBT also meets coverage criteria.

    FIT-DNA screening

    Covered when testing is performed within the stated interval.

    FIT-DNA screening: FIT-DNA testing, including Cologuard or Cologuard Plus, is limited to once every one to three years per USPSTF guidelines.Once every 1-3 years

    Coverage applies to colorectal cancer screening.

    Age and risk eligibility

    Coverage is available based on age or colorectal cancer risk.

    Eligible member population: The member is at least 45 years of age, or is younger than 45 and at risk for colorectal cancer.At least 45 years, or under 45 with colorectal cancer risk

    Risk status must be considered for members younger than 45.

    Follow-up colonoscopy

    Covered as part of the screening process when the preceding non-colonoscopy test is positive.

    Follow-up colonoscopy: A non-colonoscopy colorectal cancer screening test is positive.Positive non-colonoscopy screening test

    The colonoscopy is follow-up testing within the screening process.

    Colonoscopy and imaging-based screening intervals

    The document lists the following screening intervals.

    Accepted screening intervals: Screening colonoscopy may be performed every 10 years, CT colonography every 5 years, or flexible sigmoidoscopy every 5 years.Colonoscopy every 10 years; CT colonography every 5 years; flexible sigmoidoscopy every 5 years

    These intervals are listed under the coverage limitations section.

    Not covered screening techniques

    The following techniques do not meet coverage criteria because the policy states that sufficient published scientific literature confirming their necessity and benefit is lacking.

    Excluded techniques: Screening uses anal cytological abnormalities testing, anal HPV testing, or cell-free DNA techniques such as Guardant Shield.Any listed excluded technique

    These techniques are explicitly not covered for colorectal cancer screening.

    FIT-DNA screening

    Covered when the applicable screening or follow-up criterion is met.

    Covered FIT-DNA screening: FIT-DNA testing using Cologuard or Cologuard Plus meets coverage criteria when testing is limited to once every one to three years, per USPSTF guidelines.Once every 1-3 years

    Age and risk eligibility

    Benefit coverage applies when either age or risk criterion is met.

    Eligible member population: Benefit coverage is available for members at least 45 years of age or for members younger than 45 years of age if they are at risk for colorectal cancer.Age >=45 years OR age <45 years with colorectal cancer risk

    Follow-up and screening procedures

    A follow-up procedure meets coverage criteria when performed after a positive non-colonoscopy screening test.

    Follow-up after positive non-colonoscopy test

    • Listed modalities: Colonoscopy every 10 years; CT colonography (virtual colonoscopy) every 5 years; or flexible sigmoidoscopy every 5 years.10 years for colonoscopy; 5 years for CT colonography or flexible sigmoidoscopy

    Cell-free DNA screening

    Cell-free DNA screening was added to the coverage criteria.

    Cell-free DNA screening: Screening using cell-free DNA techniques, such as Guardant Shield, is included in the colorectal cancer screening criteria.

    Methylated Septin 9 testing using ColoVantage does not meet coverage criteria.

    Colorectal cancer screening for average-risk, asymptomatic individuals over age 75 does not meet coverage criteria.

    Screening for anal cytological abnormalities, anal HPV infection, and colorectal cancer using cell-free DNA techniques, such as Guardant Shield, does not meet coverage criteria. The policy cites insufficient published scientific literature confirming that these techniques are required and beneficial for diagnosis and treatment.

    Cologuard is not a replacement for diagnostic or surveillance colonoscopy in high-risk individuals. High-risk populations include patients with a history of colorectal cancer, adenomas, or related cancers; inflammatory bowel disease; familial adenomatous polyposis; a family history of colorectal cancer; or relevant hereditary cancer syndromes.

    Cologuard Plus is not indicated for patients with a personal history of colorectal cancer or advanced precancerous lesions; a recent positive colorectal cancer screening result, including within 6 months generally, 12 months for FOBT or FIT, or 36 months for FIT-DNA; a first-degree family history of colorectal cancer; inflammatory bowel disease; or relevant hereditary or polyposis syndromes.

    Cologuard and Cologuard Plus are intended for average-risk colorectal cancer screening. They are not substitutes for diagnostic or surveillance colonoscopy in high-risk individuals. A positive result should be followed by colonoscopy.

    The policy revision specifies that methylated Septin 9 testing using ColoVantage does not meet coverage criteria.

    Anal cytology, anal HPV testing, and cell-free DNA colorectal cancer screening techniques, such as Guardant Shield, do not meet coverage criteria because available published scientific literature does not confirm that these tests are required and beneficial for diagnosis and treatment.

    Coding and Screening Intervals

    Applicable CPT/HCPCS Procedure CodesCPT
    81327SEPT9 (Septin9) promoter methylation analysis
    81528Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result
    82270Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (ie, patient was provided 3 cards or single triple card for consecutive collection)
    82274Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations
    87624Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types
    87625Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed
    88112Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid-based slide preparation method), except cervical or vaginal
    0500TInfectious agent detection by nucleic acid (DNA or RNA), Human Papillomavirus (HPV) for five or more separately reported high-risk HPV types, genotyping
    Added colorectal cancer screening codesCPT
    0537UCode added in connection with colorectal cancer screening coverage revisions.
    0464UCode added in connection with colorectal cancer screening coverage revisions.
    Proprietary colorectal cancer screening testsCPTCovered
    0464UColorectal screening quantitative real-time target and signal amplification test for methylated DNA markers, including LASS4, LRRC4, PPP2R5C, reference marker ZDHHC1, and fecal hemoglobin, using stool and reporting a positive or negative result; proprietary test: Cologuard Plus; laboratory/manufacturer: Exact Sciences Laboratories, LLC and Exact Sciences Corporation.
    0537UOncology colorectal cancer analysis of cell-free DNA for epigenomic patterns using next-generation sequencing of more than 2500 differentially methylated regions in plasma, with an algorithm reported as positive or negative; proprietary test: Shield; laboratory/manufacturer: Guardant Health, Inc.
    Asymptomatic screening age range
    Eligible populationAsymptomatic individuals 45 to 75 years of age
    Covered testAnnual colorectal cancer screening with FIT or gFOBT
    Preferred testFIT is preferred over gFOBT
    FIT-DNA screening interval
    Covered testsFIT-DNA testing, including Cologuard and Cologuard Plus
    Screening intervalOnce every one to three years

    Provider Alerts and Denial Risks

    Denial Risk

    ColoVantage Screening Not Covered

    The use of methylated Septin 9 (ColoVantage™) for colorectal cancer screening does not meet coverage criteria.

    Denial Risk

    Screening Over Age 75 Not Covered

    For average-risk, asymptomatic individuals over 75 years of age, colorectal cancer screening does not meet coverage criteria.

    Denial Risk

    Excluded Screening Techniques

    The following colorectal cancer screening techniques do not meet coverage criteria because published scientific literature does not confirm that they are required and beneficial for diagnosis and treatment.

    • Anal cytological abnormalities screening (anal Pap smear)
    • Anal HPV infection screening

    Colorectal Cancer Screening Background

    Colorectal cancer develops in the colon or rectum and is influenced by genetic and environmental risk factors. Screening is generally performed after an individual risk assessment and focuses on detecting early colorectal cancer and adenomatous or other precancerous lesions. Available screening modalities include stool-based testing, CT colonography, flexible sigmoidoscopy, and colonoscopy. For asymptomatic individuals ages 45 to 75, annual FIT is preferred; annual gFOBT also meets coverage criteria.

    Definitions and Abbreviations

    CRC
    AbbreviationCRC
    DefinitionColorectal cancer
    Anatomic sitesCancer that develops in the colon or rectum
    FIT
    AbbreviationFIT
    DefinitionFecal immunochemical test
    Policy usePreferred annual stool-based screening test for asymptomatic individuals ages 45 to 75
    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyColorectal Cancer Screening
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionRefer a positive stool-based screening result for diagnostic colonoscopy.
    SourceLink
    On This Page
    Colorectal Cancer Screening Coverage CriteriaCoding and Screening IntervalsProvider Alerts and Denial RisksColorectal Cancer Screening BackgroundDefinitions and Abbreviations
    Guideline basis
    Per USPSTF guidelines
    Colonoscopy screening interval
    Screening modalityColonoscopy
    Screening intervalEvery 10 years
    Coverage contextListed as a covered screening option and as a modality following a positive non-colonoscopy test
    CT colonography screening interval
    Screening modalityCT colonography, also called virtual colonoscopy
    Screening intervalEvery 5 years
    Coverage contextListed among the covered screening modalities
    Flexible sigmoidoscopy screening interval
    Screening modalityFlexible sigmoidoscopy (FSIG)
    Screening intervalEvery 5 years
    Coverage contextListed among the covered screening modalities
  1. Cell-free DNA techniques, such as Guardant Shield™
  2. Billing Rule

    FIT-DNA Frequency Limitation

    FIT-DNA colorectal cancer screening with Cologuard™ or Cologuard Plus™ meets coverage criteria only when testing is limited to once every one to three years, consistent with USPSTF guidelines. Testing outside this interval may not meet coverage criteria.

    • Verify the testing interval before ordering or billing FIT-DNA screening.
    gFOBT
    AbbreviationgFOBT
    DefinitionGuaiac fecal occult blood test
    Policy useAnnual screening option for asymptomatic individuals ages 45 to 75
    FIT-DNA
    AbbreviationFIT-DNA
    DefinitionFecal immunochemical test plus DNA test (multi-target)
    Covered intervalOnce every one to three years per USPSTF guidelines
    mt-sDNA
    Abbreviationmt-sDNA
    DefinitionMulti-target stool DNA
    Test compositionA stool-based screening panel combining methylated DNA markers and hemoglobin
    IBD
    AbbreviationIBD
    DefinitionInflammatory bowel disease
    Examples identified in the policyChronic ulcerative colitis and Crohn's disease
    FAP
    AbbreviationFAP
    DefinitionFamilial adenomatous polyposis
    Risk classificationA relevant familial or polyposis syndrome associated with colorectal cancer risk
    HNPCCC
    AbbreviationHNPCCC
    DefinitionHereditary non-polyposis colorectal cancer syndrome
    Alternate name identified in the policyHNPCC or Lynch syndrome
    USPSTF
    AbbreviationUSPSTF
    Full nameU.S. Preventive Services Task Force
    RoleIndependent panel of primary care and prevention experts that provides recommendations on clinical preventive services
    CMS
    AbbreviationCMS
    Full nameCenters for Medicare and Medicaid Services
    Policy contextRegulates laboratory-developed tests as high-complexity tests under CLIA of 1988
    Multi-target stool DNA (mt-sDNA)
    TermMulti-target stool DNA (mt-sDNA)
    Test typeStool-based screening panel
    AnalytesCombines methylated DNA markers and hemoglobin to detect colorectal cancer and advanced precancerous lesions
    Asymptomatic population
    TermAsymptomatic population
    DefinitionAdults without symptoms of the condition being screened
    Recommendation contextUSPSTF recommendations in this policy apply to asymptomatic individuals
    Laboratory-developed test (LDT)
    AbbreviationLDT
    DefinitionA test validated and performed by an individual laboratory
    Regulatory contextRegulated by CMS as a high-complexity test under the Clinical Laboratory Improvement Amendments of 1988; not approved or cleared by the FDA
    Follow-up colonoscopy
    TermFollow-up colonoscopy
    When performedAfter a positive non-colonoscopy colorectal cancer screening test
    Coverage contextCovered as part of the screening process
    Cell-free DNA screening
    TermCell-free DNA screening
    DefinitionScreening based on analysis of cell-free DNA
    Example identified in the policyGuardant Shield